HUN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Huntsman Corp (HUN) is not a good buy at the moment for a beginner investor with a long-term strategy. The stock shows weak technical indicators, negative financial performance, and a lack of strong positive catalysts. Despite insider buying and some positive news about facility expansion, the overall sentiment and financial outlook are not favorable for a long-term investment.
The MACD is negative and expanding, indicating a bearish trend. The RSI is at 38.371, which is neutral but leaning towards oversold territory. Moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 11.215) with a bearish outlook, as similar candlestick patterns suggest further declines in the short term.
The company has expanded its Performance Products manufacturing facility in Hungary, which supports global demand for its products and reflects a commitment to sustainability. Insider buying has increased by 106.11% over the last month, indicating confidence from within the company.
The stock price has dropped significantly (-3.76% in the regular market and -2.84% pre-market). Analysts have mixed ratings, with some downgrades citing valuation concerns. Financial performance in Q4 2025 was weak, with revenue, net income, EPS, and gross margin all showing significant YoY declines. Technical indicators suggest a bearish trend, and the stock is expected to decline further in the short term.
In Q4 2025, Huntsman reported a revenue decline of -6.68% YoY to $1.355 billion. Net income dropped by -31.91% YoY to -$96 million, and EPS fell by -31.71% YoY to -$0.56. Gross margin also declined by -6.56% YoY to 12.1%. Overall, the financials indicate a challenging environment with declining profitability and growth.
Analysts have mixed ratings on HUN. Goldman Sachs raised the price target to $13 but maintained a Sell rating. UBS, RBC Capital, and Citi raised price targets to $55, $14, and $14, respectively, but kept Neutral or Sector Perform ratings. JPMorgan downgraded the stock to Neutral, citing valuation concerns. Mizuho raised the price target to $9 but maintained an Underperform rating. The consensus reflects cautious optimism but highlights valuation and cyclical recovery concerns.
